Delivery of curcumin nanoliposomes using surface modified with CD133 aptamers for prostate cancer
10.2147/dddt.s210949 · doi-reference
Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin
10.1002/cam4.675 · doi-reference
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
10.1371/journal.pone.0184418 · doi-reference
Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy
10.18632/oncotarget.22115 · doi-reference
Notch pathway inhibition using PF-03084014, a γ-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer
10.1158/1078-0432.ccr-15-0242 · doi-reference
Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer
10.3390/cancers15051621 · doi-reference
Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer
10.1200/jco.19.00646 · doi-reference
Imaging patients with metastatic castration-resistant prostate cancer using (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody
10.2967/jnumed.118.222844 · doi-reference
Single-arm, phase II study to evaluate the safety and efficacy of sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer who have progressed on second generation AR-directed therapy
10.1200/jco.2020.38.6_suppl.tps251 · doi-reference
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
10.1016/j.annonc.2021.03.005 · doi-reference
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer
10.1016/j.urolonc.2016.07.005 · doi-reference
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study
10.1002/pros.23922 · doi-reference
Antibody-drug conjugates come of age in oncology
10.1038/s41573-023-00709-2 · doi-reference
Exploring the next generation of antibody-drug conjugates
10.1038/s41571-023-00850-2 · doi-reference
Cleavable linkers in antibody-drug conjugates
10.1039/c8cs00676h · doi-reference
Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors
10.1093/jncics/pkz093 · doi-reference
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
10.1038/nature13229 · doi-reference
Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer
10.1016/j.celrep.2017.05.049 · doi-reference
Understanding failure and improving treatment using HDAC inhibitors for prostate cancer
10.3390/biomedicines8020022 · doi-reference
The role of histone deacetylases (HDACs) in human cancer
10.1016/j.molonc.2007.01.001 · doi-reference
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
10.1038/nature24028 · doi-reference
Targeting the p300/CBP axis in lethal prostate cancer
10.1158/2159-8290.cd-20-0751 · doi-reference
Super-enhancers in the control of cell identity and disease
10.1016/j.cell.2013.09.053 · doi-reference
Selective inhibition of tumor oncogenes by disruption of super-enhancers
10.1016/j.cell.2013.03.036 · doi-reference
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
10.1038/nature04020 · doi-reference
N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer
10.1016/j.ccell.2016.09.005 · doi-reference
The polycomb group protein EZH2 is involved in progression of prostate cancer
10.1038/nature01075 · doi-reference
Histone modifications and chromatin organization in prostate cancer
10.2217/epi.10.31 · doi-reference
Global levels of histone modifications predict prostate cancer recurrence
10.1002/pros.21038 · doi-reference
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
10.1038/s41588-020-0664-8 · doi-reference
Cancer epigenetics: From mechanism to therapy
10.1016/j.cell.2012.06.013 · doi-reference
Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy
10.1093/jnci/djv171 · doi-reference
Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss
10.1158/1078-0432.ccr-18-0981 · doi-reference
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer
10.1038/s41416-024-02614-w · doi-reference
Recent advances in targeted strategies for triple-negative breast cancer
10.1186/s13045-023-01497-3 · doi-reference
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
10.1186/s12943-023-01827-6 · doi-reference
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
10.1016/s1470-2045(23)00676-9 · doi-reference
Cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with ralaniten analogs for the treatment of androgen receptor-positive prostate and breast cancers
10.1158/1535-7163.mct-21-0411 · doi-reference
A phase Ib/II study of the CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer
10.1158/1078-0432.ccr-21-4302 · doi-reference
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
10.1136/bmjopen-2019-033667 · doi-reference
